Hypopharyngeal Neoplasms

12/01/2004 - "The purpose of this study is to evaluate the efficacy of a dose-escalated, accelerated, and hyperfractionated radiotherapy schedule with a concomitant single dose of mitomycin C in the treatment of patients with advanced laryngeal or hypopharyngeal cancer. "
12/01/2004 - "Biweekly escalated, accelerated hyperfractionated radiotherapy with concomitant single-dose mitomycin C results in a high rate of local control in advanced laryngeal and hypopharyngeal cancer."
01/01/1992 - "Peripheral blood lymphocytes obtained from 2 patients with hypopharyngeal cancer were cultured with mitomycin C treated autologous tumor cells (autologous MLTC) for 10 days and further cultured with recombinant interleukin 2 (rIL-2). "
04/01/1986 - "Chemotherapy significantly improved the survival rates in maxillary cancer, cervical esophago-hypopharyngeal cancer and malignant lymphoma in stage II. A better than partial response was obtained in 42% of the patients by a combination of Peplomycin, Vincristine, Endoxan, Mitomycin C, Predonine, 5-FU and Adriamycin. "

04/01/2013 - "The current study evaluated the efficacy of radiation and concomitant high-dose superselective intra-arterial cisplatin infusion (RADPLAT) for patients with advanced hypopharyngeal cancer. "
04/01/2013 - "Intra-arterial cisplatin with concomitant radiation for advanced hypopharyngeal cancer."
10/01/2012 - "We introduce hypopharyngeal cancer patients as the subjects that include 26 cases who underwent CCRT with high dose cisplatin (80 mg/m2 x 3: goal 240 mg/m2 in total) and also 26 cases who underwent RT during the same period. "
12/01/2015 - "Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer."
10/01/2004 - "A 72-year-old woman with hypopharyngeal cancer was treated by oral administration of S-1 and intravenous administration of low-dose cisplatin following radiation therapy. "

10/01/2005 - "Thirty-nine patients with advanced hypopharyngeal cancer received one or two cycles of intravenous administration of CDDP (80-100 mg/m2) followed by 120-hour continuous infusion of 5-FU (800-1000 mg/m2), and concomitant radiotherapy (200 cGy/day x 20-35 fractions) during the period from December, 1993 through December, 2001. "
10/01/2015 - "In order to treat the primary site without resection, superselective intra-arterial infusions with DCF anterogradely and 60 mg/m2 of DOC and 60 mg/m2 of CDDP via the femoral artery on day 1 were administered, followed by continuous intravenous instillation of 750 mg/m2/day of 5-FU for 5 days from day 2. The 5- year survival rate was 70.4% in laryngeal cancer, 72.8% in oropharyngeal cancer, and 68.5% in hypopharyngeal cancer. "
10/01/2011 - "Responders received concurrent chemoradiation with weekly cisplatin (20 mg/m(2)/day) and 5-fluorouracil (400 mg/m(2)/day) on day 1. Among 57 patients (58% with Stage IV and hypopharyngeal cancer), the rates of Grade 3-4 toxicity were 30 and 74% during induction and CCRT, respectively. "
11/01/2012 - "In consecutive series of 45 operable patients with locally advanced hypopharyngeal cancer, neoadjuvant chemotherapy by cisplatin and 5-fluorouracil was administered. "
02/01/2002 - "A 67-year-old male with advanced hypopharyngeal cancer (T3N2bM1: Stage IV) underwent two courses of superselective intra-arterial infusion of docetaxel and intravenous administration of CDDP and 5-FU. "

06/01/2013 - "These results showed that magnesium supplementation before FP treatment may be quite beneficial for preventing nephrotoxicity in patients with esophageal and hypopharyngeal cancer, and it is therefore recommended that magnesium be routinely supplemented during FP treatment for esophageal or hypopharyngeal cancer. "
06/01/2013 - "The aim of this study was to examine the effect of magnesium supplementation on the prevention of cisplatin-induced nephrotoxicity for patients with esophageal and hypopharyngeal cancer. "
06/01/2013 - "[Magnesium premedication prevents Cisplatin-induced nephrotoxicity in patients with esophageal and hypopharyngeal cancer]."
06/01/2013 - "Although patients with esophageal and hypopharyngeal cancer are susceptible to dehydration, there is no evidence yet that magnesium supplementation for these patients will prevent nephrotoxicity during cisplatin-containing chemotherapy. "

11/01/2000 - "To evaluate the utility of adriamycin in radiation therapy for hypopharyngeal cancer. "
04/01/1986 - "Chemotherapy significantly improved the survival rates in maxillary cancer, cervical esophago-hypopharyngeal cancer and malignant lymphoma in stage II. A better than partial response was obtained in 42% of the patients by a combination of Peplomycin, Vincristine, Endoxan, Mitomycin C, Predonine, 5-FU and Adriamycin. "

02/01/2011 - "[Efficacy of concurrent chemoradiotherapy with S-1 plus nedaplatin for hypopharyngeal cancer]."
02/01/2011 - "In this article, we report 6 cases with hypopharyngeal cancer treated by concurrent chemoradiotherapy with S-1 plus nedaplatin(SN therapy)in our department between January 2005 and December 2008. "
04/01/2011 - "The patient was diagnosed as having hypopharyngeal cancer(T4N2cM0)and was treated with concurrent S-1, nedaplatin and radiotherapy(hereafter referred to as SN therapy). "
04/01/2011 - "[A case of hypopharyngeal cancer successfully treated with concurrent S-1, nedaplatin and radiotherapy]."

04/01/1986 - "Chemotherapy significantly improved the survival rates in maxillary cancer, cervical esophago-hypopharyngeal cancer and malignant lymphoma in stage II. A better than partial response was obtained in 42% of the patients by a combination of Peplomycin, Vincristine, Endoxan, Mitomycin C, Predonine, 5-FU and Adriamycin. "

04/01/1986 - "Chemotherapy significantly improved the survival rates in maxillary cancer, cervical esophago-hypopharyngeal cancer and malignant lymphoma in stage II. A better than partial response was obtained in 42% of the patients by a combination of Peplomycin, Vincristine, Endoxan, Mitomycin C, Predonine, 5-FU and Adriamycin. "

04/01/1986 - "Chemotherapy significantly improved the survival rates in maxillary cancer, cervical esophago-hypopharyngeal cancer and malignant lymphoma in stage II. A better than partial response was obtained in 42% of the patients by a combination of Peplomycin, Vincristine, Endoxan, Mitomycin C, Predonine, 5-FU and Adriamycin. "

04/01/1986 - "Chemotherapy significantly improved the survival rates in maxillary cancer, cervical esophago-hypopharyngeal cancer and malignant lymphoma in stage II. A better than partial response was obtained in 42% of the patients by a combination of Peplomycin, Vincristine, Endoxan, Mitomycin C, Predonine, 5-FU and Adriamycin. "

01/01/1998 - "To evaluate the efficacy of the neoadjuvant chemotherapy and radiation therapy in treatment of patients with advanced hypopharyngeal cancer, which is notorious for its poor prognosis and severe surgical morbidity with functional deficits. "
10/01/2012 - "To improve successful larynx-preservation rates in patients with resectable, intermediate-volume hypopharyngeal cancer, a prospective trial of chemotherapy-enhanced accelerated RT was conducted. "
01/01/2005 - "The Southwest Oncology Group designed a phase II trial for patients with base of tongue or hypopharyngeal cancer to evaluate the complete histologic response rate at the primary site after induction chemotherapy followed by chemoradiotherapy for responders. "
04/01/2001 - "Among a large number of randomized trials of neoadjuvant chemotherapy, organ function preservation studies showed the possibility of laryngeal preservation for locally resectable T2 and T3 laryngeal and hypopharyngeal cancer. "
12/01/2014 - "Sequential chemotherapy administration, in the form of induction chemotherapy followed by RT or CRT, has been successful as a strategy for organ preservation in patients with potentially resectable laryngeal and hypopharyngeal cancer. "

02/01/2013 - "Our cross-sectional, observational study assesses quality of life (QOL) in patients with hypopharyngeal cancers receiving TLM plus radiotherapy (RT) compared with those treated with CCRT only or radical open surgery (nearly all of whom also received RT or CCRT). "
01/01/2013 - "The study aims to assess the feasibility of Tomotherapy-based image-guided radiotherapy (IGRT) to reduce the aspiration risk in patients with non-laryngeal and non-hypopharyngeal cancer. "
04/01/2010 - "We enrolled 30 patients with T1, T2, or selected T3 supraglottic and hypopharyngeal cancer in the study; 9 patients had undergone radiotherapy. "
09/01/2000 - "A study was designed to assess the usefulness of postoperative radiotherapy (RT) in patients with surgically treated laryngeal and hypopharyngeal cancer with histologically proven positive neck nodes. "
01/01/1996 - "A study of 141 T1-T2 cases of hypopharyngeal cancer treated by partial surgery, radical surgery or radiotherapy alone]."

07/01/2010 - "Laser surgery appears to be very effective for T1 and T2 hypopharyngeal cancer treatment as long as clear surgical margins can be achieved. "
07/01/2012 - "Laser surgery for early to moderately advanced glottic, supraglottic, and hypopharyngeal cancers."
05/01/2005 - "Organ sparing by transoral laser surgery for laryngeal and hypopharyngeal cancer has established itself within our armamentarium and its exact role will be further refined. "
03/01/1994 - "[Laser therapy of pharyngeal and hypopharyngeal cancer]."
01/01/1987 - "[Combination treatment of hypopharyngeal cancer using endoscopic laser surgery and radiation follow-up]."

08/01/2015 - "Meanwhile, the effect and prognosis was comprehensively assessed on patients with hypopharyngeal cancer reserved laryngeal function using improved submental island flaps. "
10/01/2006 - "A clinical case of a 56-year-old female with advanced hypopharyngeal cancer who had a single stage total pharyngolaryngectomy and partial oesophagectomy with reconstruction of the upper aerodigestive tract using pectoralis major pedicled flap and post operative adjunct chemo-radiation therapy. "
08/01/2015 - "A retrospective review of clinical data was performed on 38 patients of hypopharyngeal cancer reserved laryngeal function using sumental island flaps, by the way of improving in design of vascular pedicle, reconstructive mode of laryngeal and hypopharyngeal function and closing of wound of neck following hypopharyngeal cancer resection. "
03/01/2009 - "From July 2002 to February 2006, 9 cases of concomitant pharyngeal fistula (including 7 cases of laryngeal carcinoma and 2 cases of hypopharyngeal neoplasms) were repaired with submental island flaps after total laryngectomy. "

08/01/2004 - "Randomized controlled studies have shown that preservation of the larynx function in patients with advanced resectable laryngeal and hypopharyngeal cancer is possible without compromising survival compared to total laryngectomy (TL). "
07/01/1999 - "The purpose of this study was to determine the functional disabilities and overall quality of life (QOL) of patients successfully treated (ie, without evidence of disease at two years) for laryngeal or hypopharyngeal cancer by a total laryngectomy. "
04/01/1996 - "Patients with other treatment modalities and patients with positive margins of resection and laryngectomies for hypopharyngeal cancers were excluded from the study. "
01/01/2015 - "Sixteen patients with T3 or T4 laryngeal or hypopharyngeal cancer underwent a CT scan before total laryngectomy. "
01/01/2015 - "Subjective voice quality, communicative ability and swallowing after definitive radio(chemo)therapy, laryngectomy plus radio(chemo)therapy, or organ conservation surgery plus radio(chemo)therapy for laryngeal and hypopharyngeal cancer."